构建共刺激以增强T细胞受体疗法。 - Suppr

Constructing co-stimulation to boost TCR therapy.

作者信息

Höbart Julia, Ruland Jürgen

机构信息

Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany.

TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.

出版信息

Nat Cancer. 2024 May;5(5):697-698. doi: 10.1038/s43018-024-00746-9.

DOI:10.1038/s43018-024-00746-9

PMID:38816622

Abstract

摘要

相似文献

Constructing co-stimulation to boost TCR therapy.

Nat Cancer. 2024 May;5(5):697-698. doi: 10.1038/s43018-024-00746-9.

Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.

Semin Oncol. 2015 Aug;42(4):626-39. doi: 10.1053/j.seminoncol.2015.05.005. Epub 2015 Jun 12.

TCR-boosted T cell therapy yields proof-of-principle clinical data in solid cancer.

Nat Rev Drug Discov. 2024 Sep;23(9):651. doi: 10.1038/d41573-024-00121-4.

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.

Trends Pharmacol Sci. 2016 Mar;37(3):220-230. doi: 10.1016/j.tips.2015.11.004. Epub 2015 Dec 17.

Redirected T cells in cancer therapy.

Expert Opin Biol Ther. 2015;15(12):1667-70. doi: 10.1517/14712598.2015.1096340. Epub 2015 Oct 29.

Armed T cells with CAR for cancer immunotherapy.

Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15.

Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.

J Vasc Interv Radiol. 2018 Jul;29(7):1017-1021.e1. doi: 10.1016/j.jvir.2018.03.001.

TCR Gene Therapy: Challenges, Opportunities, and Future Directions.

Cells. 2020 Dec 1;9(12):2567. doi: 10.3390/cells9122567.

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.

Cells. 2020 Jun 18;9(6):1485. doi: 10.3390/cells9061485.

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9.

本文引用的文献

Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.

Nat Cancer. 2024 May;5(5):760-773. doi: 10.1038/s43018-024-00744-x. Epub 2024 Mar 19.

Long-term outcomes following CAR T cell therapy: what we know so far.

Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.

Cancer Immunol Res. 2022 Apr 1;10(4):512-524. doi: 10.1158/2326-6066.CIR-21-0307.

HLA-independent T cell receptors for targeting tumors with low antigen density.

Nat Med. 2022 Feb;28(2):345-352. doi: 10.1038/s41591-021-01621-1. Epub 2022 Jan 13.

Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.

J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003339.

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.

Nat Rev Clin Oncol. 2022 Jan;19(1):37-50. doi: 10.1038/s41571-021-00552-7. Epub 2021 Sep 27.

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.

Nat Rev Clin Oncol. 2021 Nov;18(11):715-727. doi: 10.1038/s41571-021-00530-z. Epub 2021 Jul 6.

4-1BB enhancement of CAR T function requires NF-κB and TRAFs.

JCI Insight. 2018 Sep 20;3(18). doi: 10.1172/jci.insight.121322.

Therapeutic T cell engineering.

Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395.

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Constructing co-stimulation to boost TCR therapy.

Nat Cancer. 2024 May;5(5):697-698. doi: 10.1038/s43018-024-00746-9.

Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.

Semin Oncol. 2015 Aug;42(4):626-39. doi: 10.1053/j.seminoncol.2015.05.005. Epub 2015 Jun 12.

TCR-boosted T cell therapy yields proof-of-principle clinical data in solid cancer.

Nat Rev Drug Discov. 2024 Sep;23(9):651. doi: 10.1038/d41573-024-00121-4.

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.

Trends Pharmacol Sci. 2016 Mar;37(3):220-230. doi: 10.1016/j.tips.2015.11.004. Epub 2015 Dec 17.

Redirected T cells in cancer therapy.

Expert Opin Biol Ther. 2015;15(12):1667-70. doi: 10.1517/14712598.2015.1096340. Epub 2015 Oct 29.

Armed T cells with CAR for cancer immunotherapy.

Sci China Life Sci. 2016 Apr;59(4):331-2. doi: 10.1007/s11427-016-5047-0. Epub 2016 Apr 15.

Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.

J Vasc Interv Radiol. 2018 Jul;29(7):1017-1021.e1. doi: 10.1016/j.jvir.2018.03.001.

TCR Gene Therapy: Challenges, Opportunities, and Future Directions.

Cells. 2020 Dec 1;9(12):2567. doi: 10.3390/cells9122567.

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.

Cells. 2020 Jun 18;9(6):1485. doi: 10.3390/cells9061485.

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9.

本文引用的文献

Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.

Nat Cancer. 2024 May;5(5):760-773. doi: 10.1038/s43018-024-00744-x. Epub 2024 Mar 19.

Long-term outcomes following CAR T cell therapy: what we know so far.

Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.

Cancer Immunol Res. 2022 Apr 1;10(4):512-524. doi: 10.1158/2326-6066.CIR-21-0307.

HLA-independent T cell receptors for targeting tumors with low antigen density.

Nat Med. 2022 Feb;28(2):345-352. doi: 10.1038/s41591-021-01621-1. Epub 2022 Jan 13.

Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.

J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003339.

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.

Nat Rev Clin Oncol. 2022 Jan;19(1):37-50. doi: 10.1038/s41571-021-00552-7. Epub 2021 Sep 27.

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.

Nat Rev Clin Oncol. 2021 Nov;18(11):715-727. doi: 10.1038/s41571-021-00530-z. Epub 2021 Jul 6.

4-1BB enhancement of CAR T function requires NF-κB and TRAFs.

JCI Insight. 2018 Sep 20;3(18). doi: 10.1172/jci.insight.121322.

Therapeutic T cell engineering.

Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395.

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.

Constructing co-stimulation to boost TCR therapy.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献